An early lead from the AMD070 program was optimized and a structure–activity relationship was developed for a novel series of heterocyclic containing compounds. Potent CXCR4 antagonists were identified based on anti-HIV-1 activity and Ca2+ flux inhibition that displayed good pharmacokinetics in rat and dog.